Predicting the overall response of an orthogonal 3D woven composite using simulated and tomography-derived geometry

Objectives: While Rilpivirine has shown high overall response rates in treatment-naïve patients without sex and gender specific differences in clinical trials, Sex and gender specific data in treatment experienced patients receiving rilpivirine are still limited. We conducted a 48 week efficacy and safety analysis in naïve and treatment experienced men and women using retrospective data from the HIVCENTER Frankfurt. Materials and methods: In this retrospective observational study data of all patients who received a rilpivirine based regimen at the HIVCENTER between March 2011 and December 2015 were analyzed. Primary endpoint was the proportion of patients with any discontinuation until week 48. Virologic response rates (FDA snapshot analysis; HIV-1 RNA <50 copies/mL) were assessed at week 48. Results: 194 patients (34% female) were included in the analysis. 74% were treatment-experienced and 26% naïve, respectively. Discontinuations were observed in 31 (15.9%) patients. Regarding sex differences, the proportion of discontinuations was significantly higher in women than in men (24.2% vs. 11.7%; p=0.024; ODDS-Ratio = 2.41; CI 1.12 – 5.18). Virologic failure occurred in 8 PLWHIV (4.1%). Conclusions: While virologic overall response rates to rilpivirine based ART were high for both treatment-experienced and -naïve patients the proportion of discontinuations was significantly higher in women (24.2% vs. 11.7%; p = 0.024; ODDS-Ratio = 2.41; CI 1.12 – 5.18). Although the total number of patients with virologic failure was low (4.1%), the higher rate of ART discontinuations in female patients receiving RPV require close monitoring in the first months of treatment addressing special needs of women living with HIV.

Download Full-text

Effect of geometry of dropped-off edges on the impact response of woven composite laminate with ply drops

10.1063/5.0024521 ◽

2020 ◽

Author(s):

Saurabh Kureel ◽

V. Murari

Keyword(s):

Composite Laminate ◽

Impact Response ◽

Woven Composite ◽

The Impact

Download Full-text

Improvement on Fatigue Performance of 3-D Orthogonal Woven Composite with Nanoclay Modification

Fibers and Polymers ◽

10.1007/s12221-020-0161-9 ◽

2021 ◽

Vol 22 (1) ◽

pp. 256-263

Author(s):

Xiaoping Gao ◽

Cong Wang ◽

Wei Wu ◽

Yonggui Li

Keyword(s):

Fatigue Performance ◽

Woven Composite

Download Full-text

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

Neuro-Oncology Advances ◽

10.1093/noajnl/vdaa140 ◽

2020 ◽

Vol 2 (1) ◽

Author(s):

Teresa Amaral ◽

Heike Niessner ◽

Tobias Sinnberg ◽

Ioannis Thomas ◽

Andreas Meiwes ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Local Therapy ◽

Progression Free Survival ◽

Pi3k Inhibitor ◽

Open Label ◽

Preclinical Data ◽

Overall Response ◽

Intracranial Disease ◽

Dismal Prognosis

Abstract Background Patients with melanoma brain metastasis (MBM) still carry a dismal prognosis. Preclinical data originated in xenograft models showed that buparlisib therapy was highly effective in therapy-naïve MBM. Patients and Methods In this open-label, phase II trial, we investigate the safety and efficacy of monotherapy with buparlisib, a PI3K inhibitor, in patients with asymptomatic MBM who were not candidates for local therapy. These patients had also progressed under immunotherapy if BRAF wild-type or under targeted therapy with BRAF/MEK inhibitors if carrying a BRAFV600E/K mutation. The primary endpoint was the intracranial disease control rate assessed by the investigators. The secondary endpoints were overall response rate, duration of response (DOR) of intracranial disease, overall response, progression-free survival (PFS), overall survival (OS), safety, and tolerability of buparlisib. Results A total of 20 patients were screened and 17 patients were treated with buparlisib. Twelve patients had progressed under more than 2 systemic therapy lines and 17 had received at least 1 previous local therapy. There were no intracranial responses. Three patients achieved intracranial stable disease; the median DOR was 117 days. The median PFS was 42 days (95% confidence interval [CI]: 23–61 days) and the median OS was 5.0 months (95% CI: 2.24–7.76 months). No new safety signs were observed. Conclusions Buparlisib was well tolerated but no intracranial responses were observed. These results might be explained in part by the inclusion of only heavily pretreated patients. However, preclinical data strongly support the rationale to explore PI3K inhibitor-based combinations in patients with MBM displaying hyperactivation of the PI3K–AKT pathway.

Download Full-text

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis

Therapeutic Advances in Medical Oncology ◽

10.1177/1758835920980546 ◽

2020 ◽

Vol 12 ◽

pp. 175883592098054

Author(s):

Huilin Xu ◽

Ximing Xu ◽

Wei Ge ◽

Jinju Lei ◽

Dedong Cao

Keyword(s):

Adverse Events ◽

Cancer Patients ◽

Meta Analysis ◽

Progression Free Survival ◽

Cochrane Library ◽

Good Survival ◽

Solid Cancer ◽

Cancer Type ◽

Early Effect ◽

Overall Response

Background: Immune-related adverse events (irAEs) are common during immune checkpoint inhibitor (ICI) treatment and reported to be associated with good survival. This study evaluated the association between onset timing of irAEs and survival of cancer patients treated with ICIs. Methods: Databases including PubMed, Embase, and the Cochrane library were systematically searched to retrieve clinical studies assessing the relationship between irAEs and survival in cancer patients with ICIs. The overall response rate for treatment response and hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were calculated using RevMan 5.3. Subgroup analysis in terms of cancer type, ICIs type, region, specific irAEs, accordingly. Results: A total of 34 studies were included. The HRs for OS and PFS in cancer patients with versus without irAEs were 0.57 [95% confidence interval (CI): 0.44, 0.74; p < 0.0001], and 0.50 (95% CI: 0.37, 0.67; p < 0.00001), respectively. The odds ratio for overall response in cancer patients with irAEs was 4.72 (95% CI: 3.48, 6.40; p < 0.00001) compared with those without irAEs. Subgroup analyses suggested that the prognostic role of irAEs was associated with cancer types and region, but not irAEs types. The landmark analysis of OS revealed that there is a non-proportional (early) effect of irAEs on OS in ICI-treated cancer patients (landmark >12 weeks, HROS = 1.08; 95% CI: 0.89, 1.30; p = 0.46). Conclusion: Our findings suggest that the occurrence of irAEs could be a prognostic factor for cancer patients who were treated with ICIs.

Download Full-text

Cisplatin in the treatment of recurrent childhood primary brain tumors.

Journal of Clinical Oncology ◽

10.1200/jco.1988.6.1.62 ◽

1988 ◽

Vol 6 (1) ◽

pp. 62-66 ◽

Cited By ~ 89

Author(s):

R W Walker ◽

J C Allen

Keyword(s):

Brain Tumors ◽

Germ Cell ◽

Germ Cell Tumor ◽

Overall Response Rate ◽

Response Rate ◽

Cell Tumor ◽

Primitive Neuroectodermal Tumors ◽

Primary Brain Tumors ◽

Overall Response ◽

Neuroectodermal Tumors

Thirty-three patients were treated with intravenous (IV) cisplatin (CPDD) of whom 32 were considered evaluable. There were 14 medulloblastomas, five primitive neuroectodermal tumors (PNET), nine gliomas, three ependymomas, and one germ cell tumor. The overall response rate was 13 of 32 (41%). Eleven responses (five complete [CR], five partial [PR], one mixed [MR]) were noted in the patients with medulloblastoma. The response rate within this group was 79%. Toxicity was tolerable, although it precluded further therapy in five patients.

Download Full-text